Merck & Co., Inc. — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2021-10-29

Reporting Person: Chattopadhyay Sanat (Exe V-P & Pres. MMD)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-29	Common Stock	M	24619	—	Acquired	117764.357	Direct
2021-10-29	Common Stock	S	24619	$87.32	Disposed	93145.357	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-29	Stock Option (Right to Buy)	$43.65	M	24619	Disposed	2023-05-05	Common Stock (24619)	Direct

Footnotes

F1: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F2: Holdings include shares acquired in dividend reinvestment transactions.

F3: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.